Sein métastatique RH+ HerSeq (PUMA-NER-9501) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for;Enrollment into Clinical Research Studies of Neratinib Paris, Saint-Cloud
Sein métastatique RH+ PALATINE - UC-0140/1814 ADVANCED BREAST CANCER: THERAPY INTEGRATING LOCOREGIONAL TREATMENT IN DE NOVO,;TREATMENT NAIVE, STAGE IV ER+, HER2- BREAST CANCER PATIENTS RECEIVING LETROZOLE AND;PALBOCICLIB Paris, Saint-Cloud
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
Sein métastatique RH+ SERENA-2 (D8530C00002) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase;2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus;Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast;Cancer Paris FRANCOIS-CLEMENT BIDARD
Pédiatrie Tumeurs solides CA045-020 (PIVOT IO 020) Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children,;Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) Paris FRANCOIS DOZ
Sein métastatique RH+ ESTROTIMP Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP) Paris, Saint-Cloud
Soins de support CINNAMON Evaluation of the quality of life induced by the anti-odor cinnamon dressing in patients with malodorous wounds: a multicenter randomized controlled trial. Paris
Sein métastatique RH+ SERENA-6 D8534C00001 A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, ETIENNE BRAIN
Sein métastatique RH+ EMBER-3 (J2J-OX-JZLC) EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Pédiatrie Tumeurs solides eSMART European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors. Paris ISABELLE AERTS